Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated September 25, 2025, titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Paroxetine Extended-Release Tablets USP, 25 mg and 37.5 mg".
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated September 25, 2025, titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Paroxetine Extended-Release Tablets USP, 25 mg and 37.5 mg".